





BioMatrize® uses science and deep research to help you
lose weight and keep it off for good.
We know the weight loss journey can be hard.
We’re here to make that a little easier.
We’re changing how the world thinks about weight loss.
Redefining global metabolic treatment by making advanced therapies,
such as tirzepatide and other GLP-1 agonists—accessible, safe,
and produced with unquestionable biotechnological precision.
We are a privately owned pharmaceutical company, based in Switzerland, pioneer in researching and developing innovative substance-based medical solutions.
We combine Swiss engineering, advanced research, and highly controlled manufacturing processes to deliver products with certified purity, superior stability, and maximum safety.












BioMatrize® uses science and deep research to help you lose weight and keep it off for good.
We know the weight loss journey can be hard. We’re here to make that a little easier.
We’re changing how the world thinks about weight loss.
Redefining global metabolic treatment by making advanced therapies, such as tirzepatide and other GLP-1 agonists—accessible, safe, and produced with unquestionable biotechnological precision.
We are a privately owned pharmaceutical company, based in Switzerland, pioneer in researching and developing innovative substance-based medical solutions.
We combine Swiss engineering, advanced research, and highly controlled manufacturing processes to deliver products with certified purity, superior stability, and maximum safety.



Presentation: Injectable solution / subcutaneous route.
Recomendation: Antidiabetic Weight control
Instructions Type 2 diabetes mellitus: Tirzepatide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, in combination with diet and exercise: – As monotherapy when metformin is not considered appropriate due to intolerance or contraindications. – Added to other medications for the treatment of diabetes.
Instructions Weight control: Tirzepatide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight control, including weight loss and maintenance, in adults with a baseline Body Mass Index (BMI) of: – ≥ 30 kg/m2 (obesity) or – ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).



Recomendation:
Antidiabetic Weight control
Injectable / subcutaneous.
Instructions Type 2 diabetes mellitus: Tirzepatide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, in combination with diet and exercise: – As monotherapy when metformin is not considered appropriate due to intolerance or contraindications. – Added to other medications for the treatment of diabetes.
Instructions Weight control: Tirzepatide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight control, including weight loss and maintenance, in adults with a baseline Body Mass Index (BMI) of: – ≥ 30 kg/m2 (obesity) or – ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)
Recomendation:
Antidiabetic Control
Injectable / subcutaneous.
Presentation:
Injectable / subcutaneous route.
Instructions Type 2 diabetes mellitus: Tirzepatide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, in combination with diet and exercise: – As monotherapy when metformin is not considered appropriate due to intolerance or contraindications. – Added to other medications for the treatment of diabetes.
Instructions Weight control: Tirzepatide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight control, including weight loss and maintenance, in adults with a baseline Body Mass Index (BMI) of: – ≥ 30 kg/m2 (obesity) or – ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
We create promising first-class products and support the scientific and technological development of the pharmaceutical industry.
Modern and sophisticated technology
endorsed by the best companies in the pharmaceutical sector.
Biosafety protocols with specialized protective equipment. Taking care of the exposure of all our employees within the manufacturing areas.
All processes follow international standards of:
From peptide handling to final sealing, each step is designed to maintain the highest standard of pharmaceutical safety.
A key piece for our best performance.
We have the best specialists in the development of all products, Engineers in charge of security and process automation.
We apply the latest generation of machinery
to provide the highest quality of products safety and trust is our main objective.
We create promising first-class products and support the scientific and technological development of the pharmaceutical industry.
Modern and sophisticated technology
endorsed by the best companies in the pharmaceutical sector.
We create promising first-class products and support the scientific and technological development of the pharmaceutical industry.
Modern and sophisticated technology
endorsed by the best companies in the pharmaceutical sector.
A key piece for our best performance.
We have the best specialists in the development of all products, Engineers in charge of security and process automation.
We apply the latest generation of machinery
to provide the highest quality of products safety and trust is our main objective.
We work closely with investment and pharmaceutical partners
to produce medicines for local and international markets.
Supplies more than 6000 pharmacies in 47 different countries.
Join our Business
We welcome new partnerships with companies,
who are willing to market our products in different countries.
We work closely with investment and pharmaceutical partners to produce medicines for local and international markets. Supplies more than 6000 pharmacies in 47 different countries.
Join our Business
We welcome new partnerships with companies, who are willing to market our products in different countries.
© 2026 BioMatrize Switzerland. All rights reserved.
Balz-Zimmermann-Strasse 7, 8152 Glattbrugg – Switzerland. ![]()
© 2026 BioMatrize Switzerland. All rights reserved.
Balz-Zimmermann-Strasse 7, 8152 Glattbrugg
Switzerland. ![]()